Literature DB >> 8644729

Glycine substitutions in the triple-helical region of type VII collagen result in a spectrum of dystrophic epidermolysis bullosa phenotypes and patterns of inheritance.

A M Christiano1, J A McGrath, K C Tan, J Uitto.   

Abstract

The dystrophic forms of epidermolysis bullosa (DEB) are characterized by fragility of the skin and mucous membranes. DEB can be inherited in either an autosomal dominant or autosomal recessive pattern, and the spectrum of clinical severity is highly variable. The unifying diagnostic hallmark of DEB is abnormalities in the anchoring fibrils, which consist of type VII collagen, and, recently, mutations in the corresponding gene, COL7A1, have been disclosed in a number of families. In this study, we report six families with glycine substitution mutations in the triple-helical region of type VII collagen. Among the six families, two demonstrated a mild phenotype, and the inheritance of the mutation was consistent with the dominantly inherited form of DEB. In the four other families, the mutation was silent in the heterozygous state but, when present in the homozygous state, or combined with a second mutation, resulted in a recessively inherited DEB phenotype. Type VII collagen is, therefore, unique among the collagen genes, in that different glycine substitutions can be either silent in heterozygous individuals or result in a dominantly inherited DEB. Inspection of the locations of the glycine substitutions along the COL7A1 polypeptide suggests that the consequences of these mutations, in terms of phenotype and pattern of inheritance, are position independent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644729      PMCID: PMC1914674     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  28 in total

Review 1.  Brittle bones--fragile molecules: disorders of collagen gene structure and expression.

Authors:  P H Byers
Journal:  Trends Genet       Date:  1990-09       Impact factor: 11.639

Review 2.  Molecular diagnosis of inherited skin diseases: the paradigm of dystrophic epidermolysis bullosa.

Authors:  A M Christiano; J Uitto
Journal:  Adv Dermatol       Date:  1996

Review 3.  Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis.

Authors:  B G Hudson; S T Reeders; K Tryggvason
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

4.  Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes.

Authors:  A Ganguly; M J Rock; D J Prockop
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

5.  Dominant dystrophic epidermolysis bullosa: identification of a Gly-->Ser substitution in the triple-helical domain of type VII collagen.

Authors:  A M Christiano; M Ryynänen; J Uitto
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa.

Authors:  L Hilal; A Rochat; P Duquesnoy; C Blanchet-Bardon; J Wechsler; N Martin; A M Christiano; Y Barrandon; J Uitto; M Goossens
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

7.  Evidence for a recessive PMP22 point mutation in Charcot-Marie-Tooth disease type 1A.

Authors:  B B Roa; C A Garcia; L Pentao; J M Killian; B J Trask; U Suter; G J Snipes; R Ortiz-Lopez; E M Shooter; P I Patel; J R Lupski
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

8.  Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A.

Authors:  L J Valentijn; F Baas; R A Wolterman; J E Hoogendijk; N H van den Bosch; I Zorn; A W Gabreëls-Festen; M de Visser; P A Bolhuis
Journal:  Nat Genet       Date:  1992-12       Impact factor: 38.330

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

Review 10.  Revised clinical and laboratory criteria for subtypes of inherited epidermolysis bullosa. A consensus report by the Subcommittee on Diagnosis and Classification of the National Epidermolysis Bullosa Registry.

Authors:  J D Fine; E A Bauer; R A Briggaman; D M Carter; R A Eady; N B Esterly; K A Holbrook; S Hurwitz; L Johnson; A Lin
Journal:  J Am Acad Dermatol       Date:  1991-01       Impact factor: 11.527

View more
  10 in total

1.  Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation.

Authors:  A Hovnanian; A Rochat; C Bodemer; E Petit; C A Rivers; C Prost; S Fraitag; A M Christiano; J Uitto; M Lathrop; Y Barrandon; Y de Prost
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

2.  Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa.

Authors:  B Gatalica; L Pulkkinen; K Li; K Kuokkanen; M Ryynänen; J A McGrath; J Uitto
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

3.  Sequence variants in nine different genes underlying rare skin disorders in 10 consanguineous families.

Authors:  Khadim Shah; Sabba Mehmood; Abid Jan; Izoduwa Abbe; Raja Hussain Ali; Anwar Khan; Muhammad S Chishti; Kwanghyuk Lee; Farooq Ahmad; Muhammad Ansar; Shaheen Shahzad; Deborah A Nickerson; Michael J Bamshad; Paul J Coucke; Regie L P Santos-Cortez; Richard A Spritz; Suzanne M Leal; Wasim Ahmad
Journal:  Int J Dermatol       Date:  2017-12       Impact factor: 2.736

Review 4.  Normal and abnormal mechanisms of gene splicing and relevance to inherited skin diseases.

Authors:  Vesarat Wessagowit; Vijay K Nalla; Peter K Rogan; John A McGrath
Journal:  J Dermatol Sci       Date:  2005-07-27       Impact factor: 4.563

Review 5.  Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Velina S Atanasova; Qiujie Jiang; Marco Prisco; Christina Gruber; Josefina Piñón Hofbauer; Mei Chen; Cristina Has; Leena Bruckner-Tuderman; John A McGrath; Jouni Uitto; Andrew P South
Journal:  J Invest Dermatol       Date:  2017-05-24       Impact factor: 8.551

6.  Gene localization for an autosomal dominant familial periodic fever to 12p13.

Authors:  J Mulley; K Saar; G Hewitt; F Rüschendorf; H Phillips; A Colley; D Sillence; A Reis; M Wilson
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

7.  Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis.

Authors:  David T Woodley; Yingping Hou; Sabrina Martin; Wei Li; Mei Chen
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

8.  Genetic Profile of Epidermolysis Bullosa Cases in King Abdulaziz Medical City, Riyadh, Saudi Arabia.

Authors:  Raghad Alharthi; Muhannad A Alnahdi; Ahad Alharthi; Seba Almutairi; Sultan Al-Khenaizan; Mohammed A AlBalwi
Journal:  Front Genet       Date:  2022-02-10       Impact factor: 4.599

9.  Type VII collagen gene mutations (c.8569G>T and c.4879G>A) result in the moderately severe phenotype of recessive dystrophic epidermolysis bullosa in a Korean patient.

Authors:  Jae-We Cho; Hajime Nakano; Kyu-Suk Lee
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

10.  Novel and very rare causative variants in the COL7A1 gene of Vietnamese patients with recessive dystrophic epidermolysis bullosa revealed by whole-exome sequencing.

Authors:  Thi Huyen Thuong Ma; Thi Lan Anh Luong; Thu Lan Hoang; Thi Thanh Hoa Nguyen; Thi Ha Vu; Van Khoa Tran; Duy Bac Nguyen; Tien Sang Trieu; Hai Ha Nguyen; Van Hai Nong; Dang Ton Nguyen
Journal:  Mol Genet Genomic Med       Date:  2021-07-19       Impact factor: 2.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.